Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TORNALATE vs AEROLATE JR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.
Bronchodilator for asthma,Chronic obstructive pulmonary disease (COPD)
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.
2 puffs (340 mcg) inhaled via oral inhalation 4 times daily; maximum 12 puffs/day.
1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.
Terminal elimination half-life is approximately 9-12 hours in healthy adults. May be prolonged in elderly or those with hepatic impairment, necessitating dose adjustment.
Terminal elimination half-life: 3.5-4.5 hours. This short half-life supports twice-daily dosing in asthma management, with trough levels remaining above therapeutic threshold.
Hepatic via sulfation and glucuronidation; also metabolized by catechol-O-methyltransferase (COMT).
Primarily metabolized in the liver by cytochrome P450 enzymes, including CYP1A2, CYP2E1, and CYP3A4. Metabolism is saturable at high concentrations.
Primarily renal excretion of unchanged drug and metabolites; <10% fecal. Approximately 60-70% of a dose is recovered in urine as unchanged drug and glucuronide conjugates within 24 hours.
Renal elimination: 60-70% as unchanged drug and metabolites. Biliary/fecal excretion: 20-30%.
Approximately 70% bound to plasma proteins, primarily albumin.
Approximately 70% bound to plasma proteins, primarily albumin.
Volume of distribution is approximately 1.4-2.1 L/kg, indicating extensive tissue distribution, particularly to the lungs.
Volume of distribution: 0.3-0.5 L/kg. This moderate Vd indicates distribution into total body water and some tissue binding, but limited by protein binding.
Inhalation: systemic bioavailability is about 20% due to pulmonary deposition and subsequent absorption; oral bioavailability is low (<5%) due to first-pass metabolism.
Oral bioavailability: Approximately 50% due to first-pass metabolism. Inhalation bioavailability: Variable, with 10-20% reaching systemic circulation; remainder swallowed and undergoes first-pass metabolism.
No dose adjustment required for renal impairment.
No adjustment required as drug is primarily hepatically metabolized.
No specific guidelines; caution in severe hepatic impairment due to lack of data.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
Not approved for pediatric use.
Children 4-11 years: 1 inhalation (35 mcg) twice daily; children 12-17 years: same as adult.
Use with caution; initiate at lower end of dosing range due to potential for increased sensitivity.
No specific dose adjustment; initiate at lower end of dosing range due to potential comorbidities.
None
None.
Paradoxical bronchospasm,Cardiovascular effects (tachycardia, arrhythmias),Hypokalemia,Immediate hypersensitivity reactions
Concurrent illness (especially with fever), smoking cessation, drug interactions, and hepatic or cardiac impairment can significantly alter theophylline clearance. Serum levels must be monitored due to narrow therapeutic index. Use with caution in patients with peptic ulcer, seizure disorders, or hyperthyroidism.
Hypersensitivity to TORNALATE or any component
Hypersensitivity to theophylline or any component of the formulation.
No known food interactions. Avoid excessive caffeine as it may potentiate stimulant effects.
High-fat meals may delay absorption. Charcoal-broiled foods and high-protein diets can increase clearance. Avoid concurrent consumption of large amounts of caffeine.
TORNALATE (bitolterol mesylate) is a beta-2 adrenergic agonist. Limited human data; animal studies show no teratogenic effects at clinically relevant doses. First trimester: no known risk; second/third trimester: may cause fetal tachycardia, hypoglycemia, and hyperglycemia due to beta agonist activity. Risk of preterm labor and low birth weight with chronic use. Overall, consider risk-benefit; not a major teratogen.
FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used near term due to beta-agonist effects; avoid for tocolysis.
Excretion in human milk is unknown; M/P ratio not established. Beta-2 agonists likely present in low amounts. Consider that maternal asthma control is important; benefit of breastfeeding likely outweighs minimal risk if mother is stable. Monitor infant for irritability, tachycardia, or feeding difficulties.
Excreted in breast milk; M/P ratio 2.5. Use caution; may cause tremors or tachycardia in infant. Consider risk-benefit.
No dose adjustment required for pregnancy per se. However, pregnancy may alter asthma severity; adjust dose to achieve optimal control. Monitoring for maternal tachycardia or hypokalemia may necessitate dose reduction. No established pregnancy-specific pharmacokinetic changes requiring routine dose adjustment.
Pregnancy may reduce plasma concentrations due to increased clearance; consider dose adjustment based on clinical response. Monitor for hypokalemia.
TORNALATE (bitolterol mesylate) is a selective beta-2 adrenergic agonist used as a bronchodilator. It has a faster onset than albuterol (within 3–5 minutes) but a shorter duration (3–5 hours). It is primarily indicated for acute bronchospasm in asthma or COPD. Caution in patients with cardiovascular disease, as it may cause tachycardia or arrhythmias. Not a first-line agent due to availability of longer-acting alternatives. Monitor for paradoxical bronchospasm and excessive dosing.
AEROLATE JR (theophylline) is a bronchodilator used for asthma and COPD. Due to narrow therapeutic index, monitor serum levels (target 5-15 mcg/m L). Caffeine and smoking affect metabolism; smoking cessation may require dose reduction. Avoid in seizure disorders or peptic ulcer.
Use only as directed for acute symptoms; do not exceed prescribed dose.,Rinse mouth after inhalation to prevent oral candidiasis.,Seek immediate medical help if symptoms worsen or you need more inhalations than usual.,Inform your doctor about any heart conditions, high blood pressure, or seizures.,Report side effects like chest pain, rapid heartbeat, or worsening breathing.
Take exactly as prescribed; do not change dose without consulting doctor.,Avoid excessive caffeine (coffee, tea, soda, chocolate) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, seizures.,Do not smoke or abruptly stop smoking; notify doctor if smoking habits change.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TORNALATE vs AEROLATE JR, answered by our medical review team.
TORNALATE is a Bronchodilator that works by Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.. AEROLATE JR is a Bronchodilator that works by Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TORNALATE and AEROLATE JR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TORNALATE is: 2 puffs (340 mcg) inhaled via oral inhalation 4 times daily; maximum 12 puffs/day.. The standard adult dose of AEROLATE JR is: 1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TORNALATE and AEROLATE JR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TORNALATE is classified as Category C. TORNALATE (bitolterol mesylate) is a beta-2 adrenergic agonist. Limited human data; animal studies show no teratogenic effects at clinically relevant doses. First trimester: no kno. AEROLATE JR is classified as Category C. FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used nea. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.